Drug-eluting stent

Information

  • Patent Grant
  • 7951193
  • Patent Number
    7,951,193
  • Date Filed
    Wednesday, July 23, 2008
    16 years ago
  • Date Issued
    Tuesday, May 31, 2011
    13 years ago
Abstract
A stent for delivering therapeutic agents to a body lumen includes a plurality of circumferential serpentine bands with each band comprising a plurality of struts. At least one strut has at least one first well region and at least one second well region. The at least one first well region has a first thickness, the at least one second well region has a second thickness, the first thickness being greater than the second thickness. Each well region defines a well having a depth. At least some of the wells contain a therapeutic agent.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

Not Applicable


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

Not Applicable


BACKGROUND OF THE INVENTION

1. Field of the Invention


In some embodiments this invention relates to implantable medical devices, their manufacture, and methods of use.


2. Description of the Related Art


A stent is a medical device introduced to a body lumen and is well known in the art. Typically, a stent is implanted in a blood vessel at the site of a stenosis or aneurysm endoluminally, i.e. by so-called “minimally invasive techniques” in which the stent in a radially reduced configuration, optionally restrained in a radially compressed configuration by a sheath and/or catheter, is delivered by a stent delivery system or “introducer” to the site where it is required. The introducer may enter the body from an access location outside the body, such as through the patient's skin, or by a “cut down” technique in which the entry blood vessel is exposed by minor surgical means.


Stents and similar devices such as stent, stent-grafts, expandable frameworks, and similar implantable medical devices, are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).


Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.


To prevent thrombosis and restenosis, and to treat vasculature tissue, there is a need to provide therapeutic agents directly at the site of stent deployment. One approach is through the use of medicated stents. The embodiments of the present invention provide various stent structures for containing therapeutic agents.


The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.


All U.S. patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.


Without limiting the scope of the invention, a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.


A brief abstract of the technical disclosure in the specification is provided for the purposes of complying with 37 C.F.R. §1.72.


BRIEF SUMMARY OF THE INVENTION

In at least one embodiment, the invention is directed to a stent for delivering therapeutic agents to a body lumen. The stent comprises a plurality of circumferential serpentine bands with each band comprising a plurality of struts. At least one strut has at least one first well region and at least one second well region. The at least one first well region has a first thickness, and the at least one second well region has a second thickness, the first thickness being greater than the second thickness. Each well region defines a well, each well having a depth. At least some of the wells contain a therapeutic agent.


In some embodiments, at least one second well region is positioned between two first well regions.


In at least one embodiment, the depth of at least one of the wells extends completely through the thickness of the strut.


In some embodiments, the depth of at least one of the wells extends only partially through the thickness of the strut.


In at least one embodiment, the well region comprises a durable coating, the durable coating being immediately adjacent and at least partially defining at least one well.


In some embodiments, the strut further comprises a width, and at least one of the first thickness and the second thickness have a ratio to the strut width of 1:2 strut thickness:strut width, or 2:1 strut thickness:strut width, for example.


In at least one embodiment, the present invention is directed toward a method of making a stent for delivering therapeutic agents to a body lumen. The method comprises providing at least one strut having a length, a thickness, an inner side, an outer side, and a circumference. The method further comprises creating at least one well through both the coating and the strut. The method further comprises applying a durable coating along at least a portion of the length of the at least one strut. The method further comprises depositing a therapeutic agent within the at least one well.


In some embodiments, the durable coating is applied only along at least a portion of the outer side of the at least one strut.


In at least one embodiment, the durable coating is distributed substantially evenly along at least a portion of the entire outer side.


In some embodiments, the durable coating includes applying the durable coating along at least a portion of the outer side and the inner side of the at least one strut.


In at least one embodiment, the durable coating immediately adjacent the at least one well has a first thickness, the durable coating tapering to a second thickness at a distance D from the well, the second thickness being less than the first thickness.


These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for further understanding of the invention, its advantages and objectives obtained by its use, reference should be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described embodiments of the invention.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

A detailed description of the invention is hereafter described with specific reference being made to the drawings.



FIG. 1 is an illustration of a drug-eluting stent in accordance with one embodiment of the present invention.



FIG. 2 is a perspective view of a strut with wells of a drug-eluting stent, in accordance with one embodiment of the present invention.



FIG. 3 is a perspective view of a strut with wells of a drug-eluting stent, in accordance with one embodiment of the present invention.



FIG. 4 is a cross-sectional view of the strut shown in FIG. 2.



FIG. 5 is a cross-sectional view of a strut with wells in another embodiment of the present invention.



FIG. 6 is a perspective view of a strut with wells of a drug-eluting stent, in accordance with one embodiment of the present invention.



FIG. 7 is a cross-sectional view of a strut with a durable coating, in accordance with one embodiment of the present invention.



FIG. 8 is a cross-sectional view of a strut with a durable coating, in accordance with one embodiment of the present invention.



FIG. 9 is a cross-sectional view of a strut with a durable coating, in accordance with one embodiment of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

While this invention may be embodied in many different forms, there are described in detail herein specific preferred embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.


For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.



FIG. 1 is an illustration of an embodiment of a stent for delivering therapeutic agents to a vessel in the body. A stent 10 comprising a plurality of serpentine bands 12 is depicted in FIG. 1. The serpentine bands are disposed about a longitudinal axis 14 and are arranged such that the stent has a generally tubular body 16. As seen in FIG. 1, the serpentine bands are comprised of a plurality of struts 18. At least some of the struts 18 include reservoirs or wells 20 (hereafter “wells”). As will be discussed in greater detail below, in some embodiments the wells 20 are loaded with therapeutic agents for delivery into a body lumen or vessel.


Turning now to FIG. 2, a portion of a strut 18 is depicted. Strut 18 has a variable thickness T along at least a portion of its length L. Wells 20 are placed along at least a portion of the length of the strut. In the embodiment depicted in FIG. 2, first well regions are shown at 22. A first well region 22 defines a well 20. First well regions are positioned generally at locations along the length of the strut where the thickness T is greater than adjacent regions. A second well region 24 is also depicted in FIG. 2. Second well regions are positioned generally at locations along the length of the strut where the thickness T is less than adjacent regions. For example, in FIG. 2, first well regions 22 are positioned in regions of the strut with thickness T1. And, second well regions 24 are positioned in regions of the strut with thickness T2, where T1 is greater than T2.


As mentioned above, the well regions 22, 24 define wells 20. Each well 20 extends at least partially through the strut material of strut 18. As such, each well 20 has a depth which may be less than or equal to the thickness of the strut. In an embodiment in which the depth of the well is equal to the thickness of the strut, such as is shown in FIG. 2 and the cross-sectional view of FIG. 4, the wells 20 extend completely through the thickness of the strut material. The well is open on both the outer surface 26 and the inner surface 28 in such an embodiment. In FIG. 2 the wells 20 of the first regions 22 have a depth D1 and volume V1, while the well 20 of the second region 24 has a depth D2 and volume V2, D1 being greater than D2. In an embodiment in which the depth of the well is less than the thickness of the strut, such as is shown in the cross-sectional view of FIG. 5, the wells 20 extend only partially through the thickness of the strut material such that the well is open on one of either the outer surface 26 or the inner surface 28.


It should be clear that if the wells have substantially the same dimensions with the exception of depth, than the volume V1 of the deeper wells of the first regions 22 is greater than the volume V2 of the wells located in the second regions 24. Thus the deeper wells, when filled substantially full with a therapeutic agent, provide an increased volume of therapeutic agent for delivery in comparison to wells that are less deep. Furthermore, deeper wells allow use of a barrier layer to provide a directional release gradient for the therapeutic agent, while less deep wells without such a barrier elute bidirectionally. Finally, deep wells provide a sustained release of therapeutic agent while less deep wells provide bolus doses.


In some embodiments of the invention, the strut includes two first well regions 22 separated by a second well region 24, as in FIG. 2. In at lease some embodiments, a thick-thin-thick strut design is necessary to improve the mechanical performance of the strut. Embodiments of the present invention take advantage of this necessity by placing wells within the thick-thin-thick portions in order to optimize the release of therapeutic agent into the body.


In at least one embodiment, provided along the length of the strut is a repeating pattern of a first well region, followed then by a second well region, followed then by a first well region, and followed then by a second well region, repeating as desired. In some embodiments, a strut is provided that has a single first well region followed by one or more second well regions. There are numerous first well region and second well region combinations that one of ordinary skill in the art would recognize. All of these combinations, while not explicitly detailed herein, are considered to form a portion of this disclosure.


In some embodiments, a plurality of holes within a well region is included to increase the amount of therapeutic agent which can be delivered to the site of implantation, as shown in FIG. 3. The first regions 22 and the second region 24 of FIG. 3 depict multiple holes within each well region 22, 24 in the strut 18.


Referring again to FIG. 2, it should be noted that the additional strut material which forms the added thickness of a first well region 22 extends both outwardly from the outer surface 26 of the strut as well as inwardly from the inner surface of the strut 28. This is in contrast to the embodiment depicted in FIG. 6.


As illustrated in FIG. 6, the strut material which forms the added thickness of a first well region 22 extends only outwardly from the outer surface 26 of the strut. In an alternate embodiment, the extra strut material extends only inwardly from the inner surface 28 of the strut.


Referring now to FIGS. 7-9, in some embodiments the well region 22 may comprise a durable coating 30. The durable coating 30 is placed immediately adjacent a well 20 such that it partially defines the well. Or, the durable coating 30 may be placed, as desired, onto a strut such that a well may then be created through the durable coating. In at least one embodiment, the well is created through at least a portion of the strut material. The well may be created through the durable coating and strut material by any technique known by those of ordinary skill in the art, including, but not limited to, chemical etching and laser ablation.



FIG. 7 depicts a strut 18 with a durable metallic or ceramic coating 30 placed on both the outer surface 26 and the inner surface of the strut. Durable coatings may be employed near the wells 20 to increase the overall volume of therapeutic agent 30 that can be contained within the well. In at least one embodiment, it may be desirable to apply the durable coating about the entire circumference of at least a portion of the length of a strut such that at least a portion of the outer surface, the inner surface, and the sides of the strut have the durable coating applied to them. The term circumference is meant to include the boundary of a strut, regardless of the cross-sectional characteristics of the strut. Thus, a strut with a square, rectangular, circular, semi-circular, or elliptical cross-section, or any other cross-sectional shape, has a circumference as the term is used herein.



FIG. 8 depicts a strut 18 with a durable coating 30 on only one surface of the strut, shown here as the outer surface 26. One of ordinary skill will recognize that it the durable coating can be deposited on the inner surface of the strut rather than the outer surface.



FIGS. 7-8 both depict struts with durable coatings 30 applied such that the thickness of the durable coating 30 tapers from a thickness T3 immediately adjacent the well 20 to a smaller thickness T4 as the distance D from the well 20 increases. In contrast, FIG. 9 depicts a strut with a durable coating having a thickness T3 such that as the distance D from the well increases, the thickness of the T3 remains substantially constant. Although in FIG. 9 the coating 30 is applied only on the outer surface 26, one of ordinary skill will recognize that the coating can be placed on both the outer and inner surfaces, or on only the inner surface.


One of ordinary skill in the art will recognize that there are a number of materials available that may be used as a durable coating. A non-limiting list of suitable materials includes the following: iridium oxide (IrOx), titanium oxide (TiOx), titanium dioxide (TiO2), chromium oxide (CrOx), titanium-nitrious-oxide (TiNOx), and diamond-like carbon (DLC).


Referring again to FIGS. 7-9, wells 20 are shown to contain therapeutic agent 32. A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate. In at least one embodiment, the polymer agent can be biodegradable (e.g. PLA, PLGA, etc.).


In some embodiments the at least a portion of the stent is configured to include one or more additional mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto.


In at least one embodiment of the present invention, the recoil of the stent may be reduced by optimizing the aspect ratio of the stent. That is, by increasing the thickness of the struts, and by decreasing the width of the struts, the recoil may be reduced. Desirable ratios of thickness to width are in the range of 1:2 strut thickness:strut width, or 2:1 strut thickness:strut width, for example. In such an embodiment, it may be desirable to reduce the diameter of the well to accommodate the narrower strut. In addition to reducing the recoil, the narrower strut provides the stent with a smaller profile while it is in a crimped state. The crimped profile refers to the amount of metal present in a circumferential section while the stent is crimped. The crimped profile of the stent is directly related to the ability to cross small lumen lesions.


In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.


Within the vasculature it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. At least one embodiment of the present invention is directed toward a bifurcated stent having struts with wells.


The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.


Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.


This completes the description of the preferred and alternate embodiments of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.

Claims
  • 1. A stent for delivering therapeutic agents to a body lumen, the stent comprising: a plurality of circumferential serpentine bands, each band comprising a plurality of struts, each strut having an outer surface, an inner surface, and a strut thickness between the outer surface and the inner surface, the strut thickness being variable along at least a portion of a length of the strut, at least one strut located on the strut at at least one first well region and at least one second well region, the at least one first well region located on the strut at a first strut thickness, the at least one second well region having a second strut thickness, the first strut thickness being greater than the second strut thickness, each well region defining at least one well, each well having a depth extending from the outer surface of the strut through at least a portion of the strut thickness, at least some of the wells containing a therapeutic agent.
  • 2. The stent of claim 1, wherein each well has a volume, the at least one well defined by the at least one first well region having a first volume, the at least one well defined by the at least one second well region having a second volume, the first volume being greater than the second volume.
  • 3. The stent of claim 1, wherein at least one second well region is positioned between two first well regions.
  • 4. The stent of claim 1, wherein the depth of at least one of the wells extends completely through the strut thickness.
  • 5. The stent of claim 1, wherein the well region comprises a durable coating, the durable coating being immediately adjacent and at least partially defining at least one well.
  • 6. The stent of claim 1, wherein the strut further comprises a width, and wherein at least one of the first thickness and the second thickness have a ratio to the strut width of 1:2.
  • 7. The stent of claim 1, wherein the strut further comprises a width, and wherein at least one of the first thickness and the second thickness have a ratio to the strut width of 2:1.
US Referenced Citations (227)
Number Name Date Kind
3948254 Zaffaroni Apr 1976 A
4784659 Flecksenstein et al. Nov 1988 A
5338296 Dalessandro et al. Aug 1994 A
5449382 Dayton Sep 1995 A
5464650 Berg et al. Nov 1995 A
5605696 Eury et al. Feb 1997 A
5609629 Fearnot et al. Mar 1997 A
5797898 Santini, Jr. et al. Aug 1998 A
5843172 Yan Dec 1998 A
5891108 Leone et al. Apr 1999 A
5922021 Jang Jul 1999 A
5972027 Johnson Oct 1999 A
5980564 Stinson Nov 1999 A
6063101 Jacobsen et al. May 2000 A
6071305 Brown et al. Jun 2000 A
6190404 Palmaz et al. Feb 2001 B1
6206915 Fagan et al. Mar 2001 B1
6214042 Jacobsen et al. Apr 2001 B1
6240616 Yan Jun 2001 B1
6241762 Shanley Jun 2001 B1
6254632 Wu et al. Jul 2001 B1
6273908 Ndondo-Lay Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6287628 Hossainy et al. Sep 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6325825 Kula et al. Dec 2001 B1
6379382 Yang Apr 2002 B1
6395326 Castro et al. May 2002 B1
6471721 Dang Oct 2002 B1
6471980 Sirhan et al. Oct 2002 B2
6506437 Harish et al. Jan 2003 B1
6517858 Le Moel et al. Feb 2003 B1
6521284 Parsons et al. Feb 2003 B1
6527938 Bales et al. Mar 2003 B2
6544582 Yoe Apr 2003 B1
6558422 Baker et al. May 2003 B1
6558733 Hossainy et al. May 2003 B1
6585765 Hossainy et al. Jul 2003 B1
6635082 Hossainy et al. Oct 2003 B1
6638302 Curcio et al. Oct 2003 B1
6641607 Hossainy et al. Nov 2003 B1
6652581 Ding Nov 2003 B1
6660034 Mandrusov et al. Dec 2003 B1
6663664 Pacetti Dec 2003 B1
6709379 Brandau et al. Mar 2004 B1
6709451 Noble et al. Mar 2004 B1
6716444 Castro et al. Apr 2004 B1
6725901 Kramer et al. Apr 2004 B1
6730120 Berg et al. May 2004 B2
6752826 Holloway et al. Jun 2004 B2
6753071 Pacetti Jun 2004 B1
6758859 Dang et al. Jul 2004 B1
6764505 Hossainy et al. Jul 2004 B1
6776022 Kula et al. Aug 2004 B2
6780424 Claude Aug 2004 B2
6805898 Wu et al. Oct 2004 B1
6815609 Wang et al. Nov 2004 B1
6846323 Yip et al. Jan 2005 B2
6875227 Yoon Apr 2005 B2
6884429 Koziak et al. Apr 2005 B2
6896697 Yip et al. May 2005 B1
6913617 Reiss Jul 2005 B1
6918927 Bates et al. Jul 2005 B2
6955685 Escamilla et al. Oct 2005 B2
6962822 Hart et al. Nov 2005 B2
6973718 Sheppard, Jr. et al. Dec 2005 B2
6979347 Wu et al. Dec 2005 B1
D516723 Shanley Mar 2006 S
7044965 Spielberg May 2006 B1
7070617 Kula et al. Jul 2006 B2
7105018 Yip et al. Sep 2006 B1
7114312 Coppeta et al. Oct 2006 B2
7135038 Limon Nov 2006 B1
7135039 De Scheerder et al. Nov 2006 B2
7160321 Shanley Jan 2007 B2
7163555 Dinh Jan 2007 B2
7163715 Kramer Jan 2007 B1
7169178 Santos et al. Jan 2007 B1
7223282 Hossainy May 2007 B1
7229413 Violante et al. Jun 2007 B2
7229471 Gale et al. Jun 2007 B2
7238199 Feldman et al. Jul 2007 B2
7244442 Williams et al. Jul 2007 B2
7309353 Krivoruchko Dec 2007 B2
7316710 Cheng et al. Jan 2008 B1
7335314 Wu et al. Feb 2008 B2
7393359 Verin et al. Jul 2008 B2
7410498 Penhasi Aug 2008 B2
7413846 Maloney et al. Aug 2008 B2
7416559 Shalaby Aug 2008 B2
7425217 Maier et al. Sep 2008 B2
7455753 Roth Nov 2008 B2
20020038145 Jang Mar 2002 A1
20020038146 Harry Mar 2002 A1
20020103527 Kocur et al. Aug 2002 A1
20020103528 Schaldach et al. Aug 2002 A1
20020120326 Michal Aug 2002 A1
20020123801 Pacetti et al. Sep 2002 A1
20020138136 Chandresekaran et al. Sep 2002 A1
20020155212 Hossainy Oct 2002 A1
20020183721 Santini et al. Dec 2002 A1
20020193336 Elkins et al. Dec 2002 A1
20030032892 Erlach et al. Feb 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030064095 Martin et al. Apr 2003 A1
20030069631 Stoll Apr 2003 A1
20030088312 Kopia et al. May 2003 A1
20030104590 Santini, Jr. et al. Jun 2003 A1
20030105511 Welsh et al. Jun 2003 A1
20030105512 Kanesaka Jun 2003 A1
20030153901 Herweck et al. Aug 2003 A1
20030216803 Ledergerber Nov 2003 A1
20040000540 Soboyejo et al. Jan 2004 A1
20040034337 Boulais et al. Feb 2004 A1
20040043042 Johnson et al. Mar 2004 A1
20040088038 Dehnad et al. May 2004 A1
20040093076 White et al. May 2004 A1
20040098089 Weber May 2004 A1
20040117008 Wnendt et al. Jun 2004 A1
20040133270 Grandt Jul 2004 A1
20040142014 Litvack et al. Jul 2004 A1
20040143321 Litvack et al. Jul 2004 A1
20040148010 Rush Jul 2004 A1
20040167572 Roth et al. Aug 2004 A1
20040202692 Shanley et al. Oct 2004 A1
20040204750 Dinh Oct 2004 A1
20040211362 Castro et al. Oct 2004 A1
20040236416 Falotico Nov 2004 A1
20040237282 Hines Dec 2004 A1
20040247671 Prescott et al. Dec 2004 A1
20040249449 Shanley et al. Dec 2004 A1
20050015142 Austin et al. Jan 2005 A1
20050021127 Kawula Jan 2005 A1
20050027350 Momma et al. Feb 2005 A1
20050033417 Borges et al. Feb 2005 A1
20050055080 Istephanous et al. Mar 2005 A1
20050060020 Jensen Mar 2005 A1
20050060021 O'Brien et al. Mar 2005 A1
20050074545 Thomas Apr 2005 A1
20050079199 Heruth et al. Apr 2005 A1
20050095267 Campbell et al. May 2005 A1
20050106212 Gertner et al. May 2005 A1
20050119723 Peacock Jun 2005 A1
20050136090 Falotico et al. Jun 2005 A1
20050137677 Rush Jun 2005 A1
20050137679 Changelian et al. Jun 2005 A1
20050137684 Changelian et al. Jun 2005 A1
20050159805 Weber et al. Jul 2005 A1
20050171595 Feldman et al. Aug 2005 A1
20050192657 Colen et al. Sep 2005 A1
20050196424 Chappa Sep 2005 A1
20050208100 Weber et al. Sep 2005 A1
20050209681 Curcio et al. Sep 2005 A1
20050228477 Grainger et al. Oct 2005 A1
20050228491 Snyder et al. Oct 2005 A1
20050232968 Palmaz et al. Oct 2005 A1
20050234538 Litvack et al. Oct 2005 A1
20050251245 Sieradzki et al. Nov 2005 A1
20050256564 Yang et al. Nov 2005 A1
20050261757 Shanley Nov 2005 A1
20050266039 Weber Dec 2005 A1
20050266040 Gerberding Dec 2005 A1
20050271696 Dinn et al. Dec 2005 A1
20050278929 Lee Dec 2005 A1
20050283225 Klisch Dec 2005 A1
20050287287 Parker et al. Dec 2005 A1
20060025848 Weber et al. Feb 2006 A1
20060034884 Stenzel Feb 2006 A1
20060052744 Weber Mar 2006 A1
20060053618 Verin et al. Mar 2006 A1
20060069427 Savaget et al. Mar 2006 A1
20060085065 Krause et al. Apr 2006 A1
20060100608 Uhland et al. May 2006 A1
20060129215 Helmus et al. Jun 2006 A1
20060129225 Kopia Jun 2006 A1
20060136051 Furst et al. Jun 2006 A1
20060161264 Ferreyrol Jul 2006 A1
20060171989 Prescott et al. Aug 2006 A1
20060198750 Furst et al. Sep 2006 A1
20060200229 Bugermeister et al. Sep 2006 A1
20060217801 Rosenthal Sep 2006 A1
20060224234 Jayaraman Oct 2006 A1
20060224237 Furst et al. Oct 2006 A1
20060229713 Shanley Oct 2006 A1
20060235504 Gonzales Oct 2006 A1
20060259005 Konstantino et al. Nov 2006 A1
20060269475 Ryu et al. Nov 2006 A1
20060275341 Liv et al. Dec 2006 A1
20070027530 Saint et al. Feb 2007 A1
20070032430 Fogelman et al. Feb 2007 A1
20070038176 Weber et al. Feb 2007 A1
20070043423 Grewe Feb 2007 A1
20070055352 Naimark et al. Mar 2007 A1
20070065418 Vallana Mar 2007 A1
20070065477 Parker et al. Mar 2007 A1
20070073385 Schaeffer et al. Mar 2007 A1
20070100438 Civelli May 2007 A1
20070110786 Tenney May 2007 A1
20070110888 Radhakrishnan et al. May 2007 A1
20070112414 Parker et al. May 2007 A1
20070112416 Shanley et al. May 2007 A1
20070112417 Shanley et al. May 2007 A1
20070112421 O'Brien May 2007 A1
20070151638 Burgermeister et al. Jul 2007 A1
20070173923 Savage et al. Jul 2007 A1
20070191816 Behan et al. Aug 2007 A1
20070202147 Kleiner et al. Aug 2007 A1
20070219628 Shanley et al. Sep 2007 A1
20070224116 Chandrasekaran et al. Sep 2007 A1
20070224235 Tenney et al. Sep 2007 A1
20070255393 Flanagan Nov 2007 A1
20070259116 Nolan et al. Nov 2007 A1
20080051881 Feng et al. Feb 2008 A1
20080057101 Roorda Mar 2008 A1
20080071344 Silberg et al. Mar 2008 A1
20080071349 Atanasoska et al. Mar 2008 A1
20080071351 Flanagan et al. Mar 2008 A1
20080071355 Weber et al. Mar 2008 A1
20080082162 Boismier et al. Apr 2008 A1
20080086113 Tenney et al. Apr 2008 A1
20080097349 Dillinger Apr 2008 A1
20080097569 O'Connor et al. Apr 2008 A1
20080147177 Scheuermann et al. Jun 2008 A1
20080188836 Weber et al. Aug 2008 A1
20080208325 Helmus et al. Aug 2008 A1
20080275543 Lenz et al. Nov 2008 A1
20080294236 Anand et al. Nov 2008 A1
Foreign Referenced Citations (63)
Number Date Country
3516411 Nov 1986 DE
3608158 Sep 1987 DE
19855421 May 2000 DE
10064596 Jun 2002 DE
10150995 Apr 2003 DE
10200387 Aug 2003 DE
102005010100 Sep 2006 DE
10107339 Feb 2009 DE
1132058 Sep 2001 EP
1159934 Dec 2001 EP
1235560 Sep 2002 EP
1236447 Sep 2002 EP
1254673 Nov 2002 EP
1277449 Jan 2003 EP
1308179 May 2003 EP
1310242 May 2003 EP
1348402 Oct 2003 EP
1362603 Nov 2003 EP
1402849 Mar 2004 EP
1449546 Aug 2004 EP
1319416 Nov 2004 EP
1011529 Jan 2005 EP
1570808 Sep 2005 EP
1604697 Dec 2005 EP
1685861 Aug 2006 EP
1359865 Nov 2006 EP
1779816 May 2007 EP
1886703 Feb 2008 EP
1891988 Feb 2008 EP
1891995 Feb 2008 EP
1935508 Jun 2008 EP
1952789 Aug 2008 EP
012198.7 Sep 2001 GB
2397233 Jul 2004 GB
2005160600 Jun 2005 JP
2006175017 Jul 2006 JP
9306792 Apr 1993 WO
9838946 Sep 1998 WO
0037138 Jun 2000 WO
0072907 Dec 2000 WO
0135928 May 2001 WO
0247581 Jun 2002 WO
02060506 Aug 2002 WO
03055414 Jul 2003 WO
2004006983 Jan 2004 WO
2004026281 Apr 2004 WO
2004043298 May 2004 WO
2004043292 Jul 2004 WO
2004058100 Jul 2004 WO
2004064911 Aug 2004 WO
2005051450 Jun 2005 WO
2005077305 Aug 2005 WO
2005082277 Sep 2005 WO
2005089673 Sep 2005 WO
2005110285 Nov 2005 WO
2006029708 Mar 2006 WO
2006099450 Sep 2006 WO
2007031968 Mar 2007 WO
2007031972 Mar 2007 WO
2007059253 May 2007 WO
2007118139 Oct 2007 WO
2008016528 Feb 2008 WO
2008073208 Jun 2008 WO
Related Publications (1)
Number Date Country
20100023115 A1 Jan 2010 US